Celldex announces common stock offering, no amount given

Celldex (CLDX) Therapeutics announced that it has commenced an underwritten public offering for the sale of shares of its common stock. Celldex currently intends to use the net proceeds of this offering, together with its existing cash, cash equivalents, and marketable securities, (i) to fund ongoing commercial readiness activities and the commercial launch of barzolvolimab, if approved, for the treatment of CSU in the United States, (ii) to continue the clinical and preclinical development of its product candidates, including current and future development of barzolvolimab, (iii) to grow its bispecific antibody platform and clinical candidates, (iv) to fund ongoing efforts to develop additional clinical pipeline product candidates and (v) for general corporate purposes. Leerink Partners and TD Cowen are acting as joint bookrunning managers for the proposed offering.